Morgan Stanley reiterated its Equal-Weight rating on Hospira HSP. At the moment, Morgan Stanley does not have a price target on the company's stock. On Friday, Hospira lost 1.75% of its value to end the week at $55.67.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
